Immatics NV (IMTX) Stock Price, Quote & News

Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes Anzu-cel (IMA203), a one-time infusion PRAME cell therapy, which is...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 7071 5397 0

Fax: 49 7071 5397 900

Website: www.immatics.com

Address:

Paul-Ehrlich-Strasse 15-19, Tübingen, Germany

SmallCapGrowth May. 6 at 1:00 PM

$BCTX just cleared an FDA hurdle • IND cleared for Bria-BRES+ • Phase 1/2a trial in metastatic breast cancer • Next-gen immunotherapy with enhanced immune activation Early-stage, but a meaningful step forward. NEWS: https://www.globenewswire.com/news-release/2026/05/06/3288700/0/en/briacell-receives-fda-clearance-to-initiate-bria-bres-clinical-study-in-breast-cancer.html $CRDF $IOVA $IMTX #biotech #cancer @smallcapvoice

0 · Reply

MK2020 May. 6 at 12:12 PM

$IMTX buyout incoming Proven technology

0 · Reply

JFais Apr. 28 at 8:18 PM

$IMTX - near double as clinical momentum accelerates (interim and final analyses for Anzu-cel this year, BLA submission 1H 27 with launch 2H 27 if all goes well) $IOVA

0 · Reply

Quantumup Apr. 28 at 12:17 PM

TD Cowen🏁 $IMTX at a Buy rating. $IOVA $IMCR GILD Here's what TD Cowen said in its initiation report: Immatics has the most extensive PRAME-targeted pipeline, led by anzu-cel, a TCR T-cell therapy with a low-risk Phase III readout in H2 and potentially superior efficacy, no surgical resection, and rapid 14-day manufacturing vs. Amtagvi (32 days). IMA203CD8 offers next-gen, tumor-agnostic potential, while TCERs could unlock the 1L opportunity. Our €2.3B 2035 sales estimate supports our Buy rating.

0 · Reply

SavageJohnny Apr. 26 at 5:35 AM

$IMTX Breakthrough Pediatric Remission (April 17, 2026) The stock saw a boost following news that a 17-year-old with advanced metastatic nephroblastoma (kidney cancer) achieved deep and durable remission using Immatics’ PRAME-directed TCR T-cell therapy.

1 · Reply

OfficialStocktwitsUser Apr. 23 at 1:10 AM

$IMTX RSI: 77.06, MACD: 0.3670 Vol: 0.62, MA20: 10.46, MA50: 10.13 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

Megabyte48 Apr. 21 at 10:40 PM

$IMTX i guess the miracle wasn't anything special, quiet after 5pm

1 · Reply

dgbio Apr. 18 at 10:09 AM

$IMTX Late breaking at AACR: 'Fresh point-of-care-manufactured PRAME-specific TCR T cells induced a deep antitumor response with histological, metabolic, and molecular remission evident 3 months post infusion and ongoing at 6 months follow up in a heavily pretreated pediatric patient with extensive multifocal nephroblastoma. These findings support further evaluation of PRAME-specific TCR T cell therapy in PRAME-positive pediatric cancers in a phase I/II clinical trial'. https://aacrjournals.org/cancerres/article/86/8_Supplement/LB326/783369/Abstract-LB326-Point-of-care-manufactured-PRAME?searchresult=1

1 · Reply

S_Franconi Apr. 17 at 10:25 PM

$IMTX @Trainguy1 April 17, 2026 3:00 PM EDT PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma https://investors.immatics.com/news-releases/news-release-details/prame-directed-cell-therapy-using-immatics-tcr-induces-deep-and

0 · Reply

Quantumup Apr. 14 at 10:55 AM

RBC Capital y'day⬆️the PT on $IDYA to $53 from $49 and reiterated at an Outperform rating. $IMCR $IMTX RBC Capital said in its note: Following successful topline ph.II/III data in HLA- mUM this morning, we had a chance to catch up with management, and we remain positive on the meaningfulness of IDYA's data, their regulatory strategy for daro's NDA filing in 2H26, and commercial positioning into a '27 launch. Doc feedback suggests significant enthusiasm for use, favorable read-throughs to other indications, and we think the ultimate OS readout is also likely to come in positive. We see no red flags, and with today's ~6% upside not fully reflecting the strength of the data and modest estimates in the mUM market, we remain buyers.

0 · Reply

Immatics reports Q1 EPS (43c), consensus (44c)

May 12, 2026, 7:00 AM EDT - 1 day ago

Immatics Announces First Quarter 2026 Financial Results and Business Update

2026-04-28T09:40:16.000Z - 15 days ago

Immatics initiated with a Buy at TD Cowen

Apr 21, 2026, 10:26 AM EDT - 22 days ago

Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting

2026-04-17T19:05:14.000Z - 26 days ago

Immatics abstract accepted for late-breaking poster presentation at AACR meeting

2026-03-16T13:25:11.000Z - 2 months ago

Immatics assumed with a Buy at Jefferies

2026-03-05T12:16:56.000Z - 2 months ago

Immatics sees cash runway into 2028

2026-03-05T12:07:33.000Z - 2 months ago

Immatics reports FY25 EPS (EUR 1.61) vs. EUR 0.14 last year

2026-02-19T12:28:21.000Z - 2 months ago

Immatics price target raised to $25 from $23 at Mizuho

2026-02-10T23:30:13.000Z - 3 months ago

Immatics’ treatment of Stage II and higher CM granted FDA orphan designation

2026-01-06T15:20:19.000Z - 4 months ago

Immatics price target raised to $17 from $14 at BofA

2025-12-11T12:25:41.000Z - 5 months ago

Immatics presents IMA203CD8 PRAME cell therapy data at ESMO-IO Congress

Dec 11, 2025, 7:00 AM EST - 5 months ago

Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress

2025-12-05T11:05:13.000Z - 5 months ago

Immatics announces offering of 12.5M ordinary shares

Dec 5, 2025, 6:00 AM EST - 5 months ago

Immatics Announces $125 Million Underwritten Offering

2025-11-19T13:35:44.000Z - 6 months ago

Immatics price target raised to $23 from $19 at Mizuho

2025-11-18T11:50:48.000Z - 6 months ago

Immatics price target raised to $19 from $16 at Guggenheim

2025-11-17T12:11:42.000Z - 6 months ago

Immatics reports Q3 EPS (EUR 0.42) vs (EUR 0.08) vs last year

Nov 12, 2025, 8:30 AM EST - 6 months ago

Immatics Transcript: Study Update

2025-11-12T12:30:19.000Z - 6 months ago

Immatics announces updated Phase 1a dose escalation data for IMA402, IMA401

Nov 12, 2025, 7:00 AM EST - 6 months ago

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

2025-10-29T12:58:19.000Z - 7 months ago

Immatics price target raised to $19 from $16 at Mizuho

2025-10-27T11:16:46.000Z - 7 months ago

Immatics appoints Krause as Chief People Officer

Oct 27, 2025, 7:00 AM EDT - 7 months ago

Immatics Appoints Amie Krause as Chief People Officer

2025-10-20T14:50:15.000Z - 7 months ago

Immatics highlights anti-tumor activity of anzu-cel PRAME cell therapy

Oct 20, 2025, 10:30 AM EDT - 7 months ago

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium

2025-10-01T11:05:20.000Z - 8 months ago

Immatics appoints Venkat Ramanan as Chief Financial Officer

NVS

Aug 13, 2025, 7:00 AM EDT - 9 months ago

Immatics Announces Second Quarter 2025 Financial Results and Business Update

May 31, 2025, 8:00 AM EDT - 1 year ago

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

May 13, 2025, 7:00 AM EDT - 1 year ago

Immatics Announces First Quarter 2025 Financial Results and Business Update

Apr 23, 2025, 10:00 AM EDT - 1 year ago

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

Mar 27, 2025, 7:00 AM EDT - 1 year ago

Immatics Announces Full Year 2024 Financial Results and Business Update

Nov 18, 2024, 7:00 AM EST - 1 year ago

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

Nov 8, 2024, 5:00 PM EST - 1 year ago

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Oct 10, 2024, 8:50 PM EDT - 1 year ago

Immatics Announces Pricing of $150 Million Public Offering

Oct 10, 2024, 9:00 AM EDT - 1 year ago

Immatics Transcript: Study Update

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Immatics Announces Proposed $150 Million Public Offering

Oct 10, 2024, 6:30 AM EDT - 1 year ago

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

Sep 16, 2024, 5:25 AM EDT - 1 year ago

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Immatics Announces Second Quarter 2024 Financial Results and Business Update

Jun 5, 2024, 9:00 AM EDT - 2 years ago

Immatics Transcript: Jefferies 2024 Global Healthcare Conference

May 14, 2024, 7:00 AM EDT - 2 years ago

Immatics Announces First Quarter 2024 Financial Results and Business Update

Mar 21, 2024, 7:00 AM EDT - 2 years ago

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Jan 17, 2024, 8:30 PM EST - 2 years ago

Immatics Announces Pricing of $175 Million Public Offering

Jan 17, 2024, 4:01 PM EST - 2 years ago

Immatics Announces Proposed Public Offering

Nov 14, 2023, 7:00 AM EST - 2 years ago

Immatics Announces Third Quarter 2023 Financial Results and Business Update

Nov 8, 2023, 8:30 AM EST - 2 years ago

Immatics Transcript: Study Update

Nov 8, 2023, 7:00 AM EST - 2 years ago

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

Oct 24, 2023, 7:00 AM EDT - 2 years ago

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

Sep 12, 2023, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

PLX

Sep 11, 2023, 8:59 AM EDT - 2 years ago

Immatics shares rise on Moderna cancer collaboration

MRNA

Sep 11, 2023, 7:32 AM EDT - 2 years ago

Moderna, Immatics to work jointly on cancer vaccines

MRNA

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

MRNA

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Moderna & Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

MRNA

Aug 17, 2023, 7:00 AM EDT - 2 years ago

Immatics Announces Second Quarter 2023 Financial Results and Business Update

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

Jul 24, 2023, 7:56 AM EDT - 3 years ago

Immatics shares jump after investment from Bristol Myers Squibb

BMY

Jul 24, 2023, 7:00 AM EDT - 3 years ago

Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb

May 16, 2023, 7:00 AM EDT - 3 years ago

Immatics Announces First Quarter 2023 Financial Results and Business Update

May 2, 2023, 8:30 AM EDT - 3 years ago

Immatics Transcript: Study Update

May 2, 2023, 7:00 AM EDT - 3 years ago

Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME

May 1, 2023, 7:00 AM EDT - 3 years ago

Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration

Mar 21, 2023, 7:31 AM EDT - 3 years ago

Immatics Announces Full Year 2022 Financial Results and Corporate Update

Nov 17, 2022, 7:00 AM EST - 3 years ago

Immatics Announces Third Quarter 2022 Financial Results and Business Update

Oct 10, 2022, 7:37 AM EDT - 3 years ago

Immatics Announces $110 Million Underwritten Offering of Ordinary Shares

Oct 10, 2022, 7:36 AM EDT - 3 years ago

Immatics Reports Interim Clinical Data Update on ACTengine® IMA203 TCR-T Monotherapy Targeting PRAME

Sep 10, 2022, 3:06 AM EDT - 3 years ago

Immatics Presents Comprehensive Preclinical Data Set for TCR Bispecific Candidate IMA402 Targeting PRAME at European Society for Medical Oncology (ESMO) Congress 2022

Aug 23, 2022, 7:00 AM EDT - 4 years ago

Immatics Announces First Cancer Patient Treated with Second-Generation ACTengine® TCR-T Candidate IMA203CD8 Targeting PRAME

Aug 9, 2022, 7:00 AM EDT - 4 years ago

Immatics Announces Second Quarter 2022 Financial Results and Business Update

Jun 3, 2022, 6:28 PM EDT - 4 years ago

Why you should consider buying and accumulating Immatics N.V.

Jun 2, 2022, 7:44 AM EDT - 4 years ago

Bristol Myers Squibb, Immatics expand CAR-T agreement

BMY

Jun 2, 2022, 7:05 AM EDT - 4 years ago

Immatics Announces First Quarter 2022 Financial Results and Business Update

SmallCapGrowth May. 6 at 1:00 PM

0 · Reply

MK2020 May. 6 at 12:12 PM

$IMTX buyout incoming Proven technology

0 · Reply

JFais Apr. 28 at 8:18 PM

$IMTX - near double as clinical momentum accelerates (interim and final analyses for Anzu-cel this year, BLA submission 1H 27 with launch 2H 27 if all goes well) $IOVA

0 · Reply

Quantumup Apr. 28 at 12:17 PM

0 · Reply

SavageJohnny Apr. 26 at 5:35 AM

1 · Reply

OfficialStocktwitsUser Apr. 23 at 1:10 AM

0 · Reply

Megabyte48 Apr. 21 at 10:40 PM

$IMTX i guess the miracle wasn't anything special, quiet after 5pm

1 · Reply

dgbio Apr. 18 at 10:09 AM

1 · Reply

S_Franconi Apr. 17 at 10:25 PM

0 · Reply

Quantumup Apr. 14 at 10:55 AM

0 · Reply

Quantumup Apr. 13 at 6:18 PM

Truist⬆️ $IDYA's PT to $65 from $60 and reiterated at a Buy rating. $IMCR $IMTX Truist said in its note: Today's disclosure highlights daro's best-in-class PFS and consistent efficacy to an earlier study which together with a favorable OS trend and mgmt's comfort provide meaningful derisking signals for the OS outcome (1H27E). Based on 6.9-mos mPFS and 37% ORR, we believe the daro combo is approvable via the AA pathway and could be used in both HLA-negative and HLA-positive populations. We project potential approval by YE26/early-2027, assuming a relatively aggressive regulatory timeline which could ultimately unlock our $800M+ peak revenue potential in MUM (and ~$1.7B across settings). Assigning a higher PoS, we raise our PT to $65 (from $60) and reiterate Buy.

0 · Reply

Mantraset3 Mar. 25 at 11:33 AM

$IMTX interesting 👀

0 · Reply

ArbVinnie Mar. 25 at 10:35 AM

$IMTX quite the move on earnings sheesh, they say the cashrunway is sufficent until commercialization so this seems a bit excessive

2 · Reply

StocktwitsEarnings Mar. 24 at 2:30 PM

$IMTX Q4 '25 Earnings Results & Recap Immatics expects BLA submission for anzu-cel in 1H 2027 and commercial launch in 2H 2027, with cash and cash equivalents of $551.4M extending Immatics' cash reach into 2028.

0 · Reply

notreload_ai Mar. 16 at 4:45 PM

$DSGN , $RVMD , $KYMR , $IMTX , $INSM ... Jefferies initiates Buy on Design Therapeutics ($15 PT) & assumes coverage on Revolution Medicines ($140), Kymera ($110), Immatics ($18), Insmed ($228). https://notreload.xyz/jefferies-biotech-buys-dsgn-rvmd-kymr-more-in-2026/

0 · Reply

Quantumup Mar. 16 at 11:46 AM

Cantor reit'd Top Pick $IDYA at OW. $IMCR $IMTX BMY REPL IDEAYA has guided to a progression-free survival (PFS) readout from the Ph2/3 OptimUM-02 trial of darovasertib (daro; PKC inhibitor) in 1L metastatic uveal melanoma (MUM) by the last week of March. A positive outcome could support accelerated approval in HLA-A2-negative MUM patients, and de-risk daro's potential in uveal melanoma more broadly, including in neoadjuvant, adjuvant, and HLA-agnositic disease. Based on our recent investor survey on the PFS topline, most are expecting a positive outcome. The strength of the PFS benefit will likely dictate the stock reaction. We view PFS >7 months as an upside scenario for shares (+30%). We also expect investors to use the PFS readout as an early indicator for overall survival (OS) in OptimUM-02, which could support full approval. Our investor survey suggests expectations for OS are more mixed. As such, a strong PFS benefit could alleviate concerns ahead of the interim OS analysis in 2027.

0 · Reply

S_Franconi Mar. 5 at 2:31 PM

$IMTX

0 · Reply

S_Franconi Mar. 5 at 12:34 PM

$IMTX Lots of good news here. PRAME Cell Therapy (GEN2): Data update from ongoing Phase 1a trial, with a focus on ovarian cancer at relevant doses, planned for presentation at a major medical conference in 1H 2026 https://investors.immatics.com/news-releases/news-release-details/immatics-announces-full-year-2025-financial-results-and-businessIMA203CD8

1 · Reply

BillionerOfKing Feb. 21 at 2:15 PM

$IMTX Current Stock Price: $10.06 Contracts to trade: $10.0 IMTX Mar 20 2026 Call Entry: $0.99 Exit: $1.36 ROI: 37% Hold ~25 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

houcok Feb. 5 at 3:45 PM

$IMTX The broader market is pulling this down. I have not yet seen anything specific to IMTX that could call thisnto fall.

1 · Reply

Market Cap	1.55B
Revenue (ttm)	54.61M
Net Income (ttm)	-222.26M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-407.00%
Debt to Equity Ratio	0.00

Volume	1,390,685
Avg Vol	475,868
Day's Range	N/A - N/A
Shares Out	134.07M
Stochastic %K	60%
Beta	1.31
Analysts	Strong Sell
Price Target	$18.55